Target
osteoblasts
6 products, 4 indications
Indications
Metastatic Castration-Resistant Prostate Cancer (6 products)
non-metastatic castration-resistant prostate cancer (1 products)
Advanced or metastatic prostate cancer (1 products)
metastatic hormone-naive prostate cancer (1 products)
Loading...
1 drug
1 abstract
Abstract
Real-world safety and effectiveness of radium-223 (223Ra) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated in the US: The non-interventional REASSURE study.Org: Roswell Park Cancer Institute, Advanced Radiation Centers of New York, Bayer HealthCare Pharmaceuticals Inc., Bayer Consumer Care AG,